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ABSTRACT In chronic obstructive pulmonary disease (COPD), epithelial changes and subepithelial
fibrosis are salient features in conducting airways. Epithelial-to-mesenchymal transition (EMT) has been
recently suggested in COPD, but the mechanisms and relationship to peribronchial fibrosis remain
unclear. We hypothesised that de-differentiation of the COPD respiratory epithelium through EMT could
participate in airway fibrosis and thereby, in airway obstruction.
Surgical lung tissue and primary broncho-epithelial cultures (in air–liquid interface (ALI)) from 104
patients were assessed for EMT markers. Cell cultures were also assayed for mesenchymal features and for
the role of transforming growth factor (TGF)-β1.
The bronchial epithelium from COPD patients showed increased vimentin and decreased ZO-1 and
E-cadherin expression. Increased vimentin expression correlated with basement membrane thickening and
airflow limitation. ALI broncho-epithelial cells from COPD patients also displayed EMT phenotype in up
to 2 weeks of culture, were more spindle shaped and released more fibronectin. Targeting TGF-β1 during
ALI differentiation prevented vimentin induction and fibronectin release.
In COPD, the airway epithelium displays features of de-differentiation towards mesenchymal cells,
which correlate with peribronchial fibrosis and airflow limitation, and which are partly due to a TGF-β1-
driven epithelial reprogramming.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a frequent chronic disease causing a major health
burden and will become the third most common cause of death by 2030 [1]. It is associated with
abnormal airway and alveolar responses to noxious exposure, usually to cigarette smoke. Chronic
inflammation with activation of neutrophils and macrophages and imbalance between proteinases/
anti-proteinases and oxidants/anti-oxidants have been implicated in this process [2]. In addition, structural
changes in COPD are also present and differ between airways and alveoli. In contrast to respiratory
bronchioles and alveoli which are disrupted, causing so-called emphysema, matrix deposition and
subepithelial fibrosis are present in conducting airways, along epithelial changes. It is likely that airway
fibrosis and parenchymal emphysema underlie the irreversible nature of airway obstruction, which is
mostly insensitive to current therapies [3].
The airway epithelium assures frontline innate defence mechanisms, through a physical barrier and
secretion of protective factors. The barrier function is provided by apical complexes of tight junctions
containing zonula occludens-1 (ZO-1) protein that binds occludin and adherens junctions with β-catenin
that binds transmembrane E-cadherin. In addition, ZO-1 and β-catenin bind to the actin cytoskeleton [4].
The phenotype of the adult human respiratory epithelium remains “flexible”, this plasticity being required
to maintain epithelial integrity following injury. Normal airway epithelial repair involves the rapid
de-differentiation of airways epithelial cells to produce squamous cells (metaplasia), which is reversible and
mediates restitution of the normal airway [5]. The epithelium is then repopulated via resident basal cells,
which proliferate and differentiate to form a new epithelium [6]. In addition, airway epithelial cells may
dedifferentiate through so-called epithelial-to-mesenchymal transition (EMT), to become able to migrate
and to secrete matrix proteins, before differentiating into ciliated or goblet cells. Epithelial cells typically
lose, transiently, their epithelial characteristics, with loss of polarity and junctional proteins (such as ZO-1
and E-cadherin), and acquire mesenchymal features such as spindle shape, vimentin filaments and
secretion of matrix fibronectin [5, 7].
The airway fibrosis observed in COPD is mainly peribronchial, within the adventitia of small airways. In
contrast, in asthma, the prominent deposition of extracellular matrix just beneath the epithelial basement
membrane occurs in the lamina propria of both large and small airways [8]. In addition, several changes
of the bronchial epithelium have been reported in COPD; these include goblet cell hyperplasia and
squamous cell metaplasia [9]. EMT participates in normal lung biology during development (airway
branching) and repair, but is also observed during cancer progression and metastasis [10]. While alveolar
EMT has been reported in lung fibrosis [11], three recent studies suggest that EMT also occurs in COPD
airways [12–14]. However, the underlying mechanisms and the functional consequences of EMT in the
conducting airways from COPD patients remain unclear.
The present study was therefore designed to assess EMT features of the COPD airway epithelium, both in
tissue and in broncho-epithelial cultures differentiated upon air-liquid interface (ALI), hypothesising that
EMT in conducting airways from COPD represents an intrinsic feature of the diseased epithelium which
contributes to peribronchial fibrosis and thereby, to irreversible airway obstruction. Some of the results of
this study have been reported in the form of an abstract at the ERS International Congress 2013 and at the
Lung Science Conference 2014 [15, 16].
Materials and methods
Additional details are provided in the online supplementary material.
Study subjects
104 patients were enrolled in this study, consisting of 42 controls (26 smokers or ex-smokers, and 16
nonsmokers) and 62 COPD patients, namely 21 mild (Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage I), 22 moderate (GOLD stage II) and 6 severe COPD (GOLD stage III) undergoing
lung resection surgery for a solitary tumour and recruited between 2007 and 2013 (table 1). Lung explants
from 13 very severe COPD (GOLD stage IV) patients were also included. For all patients, a detailed
clinical history was available and all underwent lung function testing. Patients with other lung diseases
(such as asthma) were excluded from the study. All patients gave signed informed consent to the study
protocol.
Lung tissue sampling and processing
Lung sections (containing large and small airways) were obtained from the surgical specimens and
processed for immunohistochemistry. One additional large airway sample was obtained for primary
epithelial cell culture. According to optimal quality of samples, among the 104 enrolled patients (table 1)
expression analyses (immunohistochemistry, polymerase chain reaction) were performed for 51 patients
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(table E1 in the online supplementary material) and primary broncho-epithelial cultures were derived
from 69 patients (table E2 in the online supplementary material). In addition, small conducting airways
(membranous bronchioles, diameter ⩽2 mm) were sampled for immunolocalisation in whole tissue by
multiphoton microscopy.
Primary cultures of human bronchial epithelial cells
A piece of large, cartilaginous bronchus away from the tumour site was selected to derive human
broncho-epithelial cells (HBEC). Cultures were carried out in air/liquid interface (ALI) for 2 weeks, to
allow re-differentiation into a pseudo-stratified, mucociliary airway epithelium [5]. Cytospins were
performed both before starting culture and at 10 days of culture, in submerged conditions. For blocking
experiments, anti-human transforming growth factor (TGF)-β1 antibody or control mouse
immunoglobulin (Ig)G was added (every other day with fresh medium) during the 2 weeks of ALI. No
significant cytotoxicity was observed (release of lactate dehydrogenase <10%) in the presented conditions.
For kinetics experiments, ALI cultures were carried out for 1–5 weeks and compared with submerged
cultures.
Immunoassays for epithelial/mesenchymal markers
Immunophenotyping for epithelial and mesenchymal markers
Serial paraffin sections of lung tissue and of HBEC filters were stained for junctional proteins (ZO-1,
E-cadherin), epithelial lineage markers (p63, β-tubulin IV, MUC5AC) and vimentin. Quantification of the
staining intensity was carried out in 10 fields per section by using ImageJ software (National Institutes of
Health, Bethesda, MD, USA), and results were expressed as the percentage of positive/stained area within
the epithelium for ZO-1 and E-cadherin. Counting of vimentin-positive cells was performed manually,
considering positive columnar cells and excluding intraepithelial leukocytes which also express vimentin
(CD45 staining; fig. E1 in the online supplementary material). Thickness of the reticular basement
membrane (RBM) was assessed according to the Wilson’s method [17]. In immunofluorescence, tissue and
HBEC paraffin sections were stained for low molecular weight cytokeratins and vimentin.
Western blot for epithelial/mesenchymal markers
HBEC were assayed for E-cadherin, vimentin, ZO-1, low molecular weight cytokeratin and fibronectin
expression by western blot and quantification was carried out by using Quantity One software (Bio-Rad
Laboratories, Hercules, CA, USA).
ELISA for fibronectin
Fibronectin release was assessed by direct or sandwich ELISA of the basolateral medium in ALI cultures.
TABLE 1 Patient characteristics of the study population
Controls COPD All
Nonsmokers (Ex-)smokers Mild Moderate Severe
Subjects n 16 26 21 22 19 104
Female/male sex n 13/3 11/15 3/18 5/17 7/12 39/65
Smoking history pack–years
(n=99) (never/former/current n)
0#+¶§ (16/0/0) 27±16ƒ§ (0/15/11) 38±18ƒ (0/10/11) 43±17ƒ (0/7/15) 48±25#ƒ (0/15/4) 32±23 (16/47/41)
Inhaled corticosteroids n 1 2 1 5 15 24
Inhaled corticosteroids, BDP
equivalent µg·day−1 (N=21)
568 1269±1418 2272 1737±898 2199±2721 1949±2190
Age years 62±15 61±16 65±10 65±10 60±5 63±12
BMI kg·m−2 25.8±3.9 24.5±4.3 26.1±6.1§ 24.2±4.2 22±4.3+ 24.4±4.8
FEV1 % predicted (N=102) 93±19¶§ 95±24¶§ 95±15¶§ 68±8ƒ#+ 29±13ƒ#+ 77±30
FEV1/VC ratio % (N=101) 77±7+¶§ 79±8+¶§ 65±3ƒ#§ 61±9ƒ#§ 34±11ƒ#+¶ 64±18
DLCO % predicted (N=79) 77±14§ 75±16§ 72±22§ 58±17 36±15ƒ#+ 64±22
Data are presented as mean±SD, unless otherwise stated. Demographic data, lung function tests, smoking history and inhaled corticotherapy
are stated for the patient groups, classified according to smoking history and the presence of airflow limitation. Patients with other lung
diseases were excluded from the study. N is specified when data are missing. BDP: beclomethasone diproprionate; BMI: body mass index;
FEV1: forced expiratory volume in 1 s; VC: vital capacity; DLCO: diffusing capacity of the lung for CO. #: p<0.05 versus (ex-)smokers; +: p<0.05
versus mild COPD; ¶: p<0.05 versus moderate COPD; §: p<0.05 versus severe COPD; ƒ: p<0.05 versus nonsmokers.
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Real-time quantitative polymerase chain reaction analysis for ZO-1, E-cadherin, and vimentin
mRNA
Total RNA was isolated from HBEC and reverse-transcribed. Expression levels of ZO-1, E-cadherin and
vimentin, mRNA were quantified by Real-time quantitative polymerase chain reaction (RT-qPCR) and
normalised to the geometric mean of housekeeping genes (glyceraldehyde-3-phosphate dehydrogenase and
ribosomal protein S18) [18].
Multiphoton imaging of small airways stained for vimentin, laminin and E-cadherin
Dissected small airways from one control smoker and two severe COPD patients were treated as described [19].
Whole tissue was immunostained for E-cadherin (epithelial marker), laminin (RBM marker) and vimentin
(mesenchymal marker). Fluorescent labelling was observed with a LSM510 multiphoton confocal microscope.
Statistical analysis
Results were expressed as medians and interquartile ranges, unless otherwise stated. A p-value <0.05 was
considered statistically significant.
Results
Reduced expression of epithelial markers in the COPD airway epithelium
In our study population (table 1), we first addressed whether EMT was potentially present in conducting
airways of COPD patients, lung sections from COPD versus control patients were immunostained for
junctional markers of the epithelium. In the large airway epithelium from COPD patients, ZO-1
expression was decreased in mild and moderate COPD (fig. 1a and b). E-cadherin expression was also
decreased in COPD airways, compared with nonsmokers (fig. 1a and c).
Increased expression of vimentin in the COPD airway epithelium
Vimentin-expressing epithelial cells were then analysed as key markers of EMT-related de-differentiation.
These cells were increased in both large and small airways from COPD patients (fig. 2a–c). In addition,
epithelial expression of vimentin correlated with airway obstruction in terms of post-bronchodilator forced
expiratory volume in 1 s (FEV1) and FEV1/vital capacity (VC) ratio, both in large (fig. 2d and e) and
small airways (fig. 2f and g). In contrast, E-cadherin expression positively correlated with FEV1/VC ratio
(r=0.41, p=0.006; not shown). Moreover, expression of epithelial and mesenchymal markers was correlated
to each other (table E3 in the online supplementary material).
Multiphoton imaging of small airways (bronchioles) immunostained for vimentin, E-cadherin and laminin
demonstrated that the microlocalisation of vimentin-expressing columnar epithelial cells was correlated
with the accumulation of vimentin in subepithelial tissue (fig. 3a, left and middle panel, video E1 in the
online supplementary material). Co-localisation of vimentin and low molecular weight cytokeratin to these
intraepithelial cells indicated the epithelial origin of these cells (fig. 3a, right panel). We also found RBM
thickening (fig. 3b and c) and increased number of clefts (fig. 3b and d) in the RBM of airways from
COPD patients compared with controls. The number of clefts was correlated to RBM thickness (r=0.491;
p<0.0001). In addition, RBM thickness was correlated with epithelial expression of vimentin (fig. 3e) and
with airflow limitation (FEV1) (fig. 3f). Together, these data confirm the presence of EMT in both large
and small airways of COPD patients and showed that this epithelial process correlates with peribronchiolar
fibrosis and airway obstruction.
EMT features of the bronchial epithelium from COPD patients persist in vitro
In order to evaluate whether EMT could represent an intrinsic feature of the COPD airway epithelium, we
used ALI-HBEC as an in vitro model to study the (re)differentiation process (fig. 4a). We found that the
bronchial epithelium reconstituted from large airway tissue of COPD patients cultured upon ALI for
2 weeks, displays decreased expression of ZO-1 and E-cadherin (fig. 4b–d), as observed in situ. ZO-1 and
E-cadherin mRNA showed a trend to decrease in cultures coming from COPD patients without reaching
statistical significance (fig. 4e and f). In addition, expression levels of ZO-1 and E-cadherin in ALI-HBEC
were correlated with airway obstruction, in terms of FEV1 and FEV1/VC ratio (fig. 4g and fig. E2 in the
online supplementary material).
Increased vimentin expression was also recapitulated in the ALI-cultured epithelium from severe COPD
(fig. 5a and c). Co-localisation of cytokeratin and vimentin by immunofluorescence allowed us to exclude
fibroblast contamination of the epithelium (fig. 5b). In addition, vimentin induction in HBEC from COPD
patients was also observed at the mRNA level (fig. 5d) and was negatively correlated with FEV1 and FEV1/
VC ratio at the protein level (fig. 5e and f). The mesenchymal profile of the COPD airway epithelium was
confirmed by western blot analysis for epithelial and mesenchymal proteins, clearly showing decreased
E-cadherin and increased vimentin and fibronectin expression (fig. 5g).
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FIGURE 1 Epithelial immunostaining in lung tissue. a) Immunohistochemistry for zonula occludens-1 (ZO-1) and
E-cadherin in large airways of a nonsmoker, a smoker and a severe chronic obstructive pulmonary disease (COPD)
patient. b) Quantification of ZO-1 staining in large airways (n=47; empty diamonds represent data from transplanted,
Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV patients). c) Quantification of E-cadherin
staining in large airways (n=47; empty diamonds represent data from transplanted, GOLD stage IV patients). *: p<0.05;
#: p=0.006; ¶: p=0.001. Scale bars=50 µm.
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FIGURE 2 Vimentin immunostaining in lung tissue. a) Immunohistochemistry for vimentin in large and small airways of a nonsmoker and a severe chronic obstructive pulmonary disease
(COPD) patient. Scale bars=50 µm. b) Quantification of vimentin staining in large airways (n=48; empty diamonds represent data from transplanted, Global Initiative for Chronic Obstructive
Lung Disease (GOLD) stage IV patients). c) Quantification of vimentin staining in small airways (n=40; empty diamonds represent data from transplanted, GOLD stage IV patients). d)
Correlation between vimentin staining and forced expiratory volume in 1 s (FEV1) in large airways. e) Correlation between vimentin staining and FEV1/vital capacity (VC) ratio in large airways.
f) Correlation between vimentin staining and FEV1 in small airways. g) Correlation between vimentin staining and FEV1/VC ratio in small airways. *: p<0.05; #: p=0.011; ¶: p=0.01.
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FIGURE 3 Subepithelial fibrosis in chronic obstructive pulmonary disease (COPD). a) Left and middle panels:
immunolocalisation of vimentin (in blue), laminin (green) and E-cadherin (red), in a control and a COPD patient. Scale
bars=20 µm. Right panels: co-immunolocalisation of vimentin (green) and low molecular weight cytokeratin (red), in a
goblet and a ciliated cell from a COPD patient. Round, single vimentin-positive cells correspond either to basal cells or
intraepithelial leukocytes. Scale bars=10 µm. b) Colocalisation of vimentin-positive cells and thickened reticular
basement membrane (RBM) in a severe COPD patient. Scale bar=50 µm. c) Quantification of RBM thickness in large
airways (n=48; empty diamonds represent data from transplanted, Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage IV patients). d) Quantification of RBM clefts in large airways (n=48; empty diamonds represent
data from transplanted, GOLD stage IV patients). e) Correlation between RBM thickness and epithelial vimentin
staining in small airways. f ) Correlation between RBM thickness and forced expiratory volume in 1 s (FEV1). *: p<0.05;
#: p=0.03; ¶: p=0.0011.
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FIGURE 4 Epithelial immunostaining in human broncho-epithelial cells (HBEC) in controls, mild (to moderate) and severe chronic obstructive pulmonary disease
(COPD) patients. a) Model of HBEC cultured in air-liquid interface (ALI), from proximal lung tissue. b) Immunohistochemistry for zonula occludens-1 (ZO-1) and
E-cadherin in ALI–HBEC from a nonsmoker and a severe COPD patient. Scale bars=50 µm. c) Quantification of ZO-1 staining (n=27; in controls filled circles
represent nonsmokers and, in severe COPD, empty triangles represent data from transplanted, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage
IV patients). d) Quantification of E-cadherin staining (n=28; in controls, filled circles represent nonsmokers and, in severe COPD, empty diamonds represent data
from transplanted, GOLD stage IV patients). e) Expression of ZO-1 mRNA by RT-qPCR in ALI–HBEC from controls and COPD patients, normalised to the
geometric mean of the two housekeeping genes (n=37; empty diamonds represent data from transplanted, GOLD stage IV patients). f) Expression of E-cadherin
mRNA by RT-qPCR in ALI–HBEC from controls and COPD patients, normalised to the geometric mean of the two housekeeping genes (n=37; empty diamonds
represent data from transplanted, GOLD stage IV patients). g) Correlation between ZO-1 staining and forced expiratory volume in 1 s (FEV1) values. #: p=0.03; ¶:
p=0.01.
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FIGURE 5 Vimentin immunostaining in human broncho-epithelial cells (HBEC) in controls, mild (to moderate) and
severe chronic obstructive pulmonary disease (COPD) patients. a) Immunochemistry for vimentin in air-liquid interface
(ALI)–HBEC from a nonsmoker and a severe COPD patient. b) Immunofluorescence for co-localisation of vimentin in
green and low molecular weight cytokeratin in red in ALI–HBEC from a severe COPD patient. Scale bars=50 µm. c)
Quantification of vimentin staining (n=28; in controls, filled circles represent nonsmokers and, in severe COPD, empty
triangles represent data from transplanted, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV
patients). d) Expression of vimentin mRNA, corrected for the geometric mean of the two housekeeping genes (n=37;
empty diamonds represent data from transplanted, GOLD stage IV patients). e) Correlation between vimentin staining
and forced expiratory volume in 1 s (FEV1) values in COPD patients (n=14). f ) Correlation between vimentin staining
and FEV1/vital capacity (VC) ratio in COPD patients (n=14). g) Immunoblots for epithelial and mesenchymal proteins,
as referred to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), in ALI–HBEC from three nonsmokers and three
severe COPD patients. LMW CK: low molecular weight cytokeratin; ZO-1: zonula occludens-1. #: p=0.006; ¶: p=0.004.
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Epithelial ZO-1 and E-cadherin were correlated with each other (r=0.57, p=0.002; and r2=0.31, p=0.003).
When data obtained in lung tissue and HBEC from the same patients (n=13) were compared, significant
correlation was observed between in vitro and in situ expression levels of ZO-1 but also between different
epithelial junctional proteins (ZO-1 and E-cadherin in tissue) (table E4 in the online supplementary
material). In addition, E-cadherin expression in HBEC was negatively correlated with vimentin expression
in small airway tissue (table E4 in the online supplementary material). Altogether, these data show that
the bronchial epithelium reconstituted in vitro from large airway tissue of COPD patients retains EMT
features observed in situ, in both large and small airways.
Mesenchymal features of the cultured bronchial epithelium from COPD patients
Besides vimentin expression, we next evaluated other mesenchymal features of COPD HBEC, namely the
morphology and release of matrix proteins. First, HBEC from some COPD patients were morphologically
more spindle-shaped cells compared to the classical cobble-stone aspect of epithelial cells from controls
(fig. 6a). Secondly, HBEC from some COPD patients (at 2 weeks of ALI) were able to release fibronectin,
which was observed with none of the control HBEC (fig. 6b).
Reversibility of EMT features of the cultured COPD bronchial epithelium
We then wondered whether EMT features observed in the COPD bronchial epithelium (in situ and
recapitulated in vitro) related to a reversible reprogramming. To address this issue, the cultured bronchial
epithelium was assessed for EMT markers by western blot from the submerged condition to 5 weeks of
ALI differentiation (fig. 6c). In the control epithelium, we observed that epithelial markers (E-cadherin
and low molecular weight cytokeratins) were upregulated upon ALI, whereas vimentin expression observed
in the undifferentiated submerged epithelium was rapidly lost (at 1 week of ALI; fig. 6c), as observed for
fibronectin release in the culture medium (fig. 6d). In cultures from COPD patients, epithelial proteins,
barely detectable in the submerged conditions, increased upon ALI culture but without reaching the level
(particularly for cytokeratins) of the control epithelium. Moreover, expression of the mesenchymal
markers vimentin and fibronectin, detected in submerged cultures, persisted up to 2 weeks of ALI before
progressively declining. This progressive loss of mesenchymal features was corroborated by fibronectin
release data (fig. 6e). Finally, assessing the phenotype of bronchial cells before culturing them and after
10 days of submerged culture showed that vimentin positive cells were present in the originally sampled
tissue and thereafter decreased upon culture, before the ALI-driven re-differentiation (fig. 6f ).
These results show that EMT features reactivated in vitro upon ALI culture, presumably in cells that are
present in the initial biopsy sample, are not persistent and progressively reverse upon the culture
conditions.
Contribution of TGF-β to EMT reprogramming of the COPD bronchial epithelium
We next assessed whether TGF-β, a major inducer of EMT, could contribute to imprint the COPD
epithelium for EMT. First, we confirmed that treating the epithelium with exogenous TGF-β1 induced
vimentin expression, particularly in the basal layer (fig. 7a and b), as well as fibronectin release (fig. 7d).
Conversely, we observed that neutralising TGF-β1 (by using a blocking monoclonal antibody) during the
2 weeks of ALI downregulated vimentin expression (p=0.03), both in control and COPD HBEC, while
control mouse IgG had no significant effect (fig. 7b). The morphological appearance changed upon
treatment with anti-TGF-β1, restoring a cobble-stone shape compared with the spindle-shaped, untreated
COPD cells (fig. 7c). In addition, fibronectin release was dose-dependently decreased in ALI-HBEC treated
by anti-TGF-β1 antibodies (fig. 7d and e). Together, these data show that the TGF-β pathway is involved
in the EMT programming of airway epithelial cells from COPD patients.
Discussion
This study provides further evidence that EMT occurs in the conducting airways from COPD patients and
shows for the first time that de-differentiation and EMT features of the COPD bronchial epithelium
correlate with subepithelial fibrosis and airway obstruction. In addition, it also shows that these
mesenchymal features are reactivated in vitro, during the first weeks of ALI-driven differentiation of the
epithelium reconstituted in vitro from COPD airway tissue, and result at least in part from a reversible
reprogramming by TGF-β.
Dysregulated EMT in the diseased lung was first suggested in parenchymal fibrosis, the alveolar epithelium
from patients with idiopathic pulmonary fibrosis showing evidence of EMT and activation of the Wnt/
β-catenin pathway [20]. It was also shown that EMT could be induced in vitro in (human and rat) alveolar
epithelial cells, notably by TGF-β [21]. In contrast, the occurrence and relevance of EMT in chronic airway
diseases remains debated [22, 23]. Findings in experimental asthma and in vitro epithelial responses to
TGF-β and allergens suggested a role for EMT in allergic asthma [24], but direct evidence of constitutive
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FIGURE 6 Mesenchymal features of human broncho-epithelial cells (HBEC) from chronic obstructive pulmonary disease (COPD) patients. a) Morphological
aspect of air-liquid interface (ALI)–HBEC from a control versus a COPD patient. Scale bar=100 µm. b) Fibronectin release by HBEC from controls versus
COPD, at 2 weeks of ALI (n=35). c) Kinetics of epithelial and mesenchymal markers expression in HBEC, cultured in submerged condition and in ALI
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low molecular weight cytokeratin; ZO-1: zonula occludens-1. *: p<0.05; #: p=0.02; **: p<0.01.
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overexpression of mesenchymal markers by the asthmatic bronchial epithelium is lacking. EMT in
conducting airways was shown in post-transplant bronchiolitis [25], as well as in chronic rhino-sinusitis
[26]. In COPD, SOHAL and colleagues [12, 13] observed in large airways from COPD patients the presence
of clefts within the RBM containing S100A4/vimentin/ matrix metallopeptidase (MMP)-9 positive
epithelial cells, presumably migrating from the surface epithelium to the lamina propria. MILARA et al. [14]
recently reported EMT features in small airways of smokers and COPD patients and in undifferentiated
(submerged) primary broncho-epithelial cells from COPD patients. It was shown in vitro that cigarette
smoke is also able, per se, to induce EMT [14, 27]. However, in our data, ZO-1 was not affected in situ, in
the airway epithelium from smokers, suggesting that ZO-1 downregulation may only concern susceptible
smokers who have developed COPD. Our study of large and small airways from COPD and control patients
confirms the presence of de-differentiated epithelial cells engaged in EMT at both levels, suggesting that
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FIGURE 7 Regulation of vimentin and fibronectin expression by transforming growth factor (TGF)-β1 and blocking
experiments of TGF-β1. a) Effect of TGF-β1 (10 ng·mL−1), blocking anti-TGF-β1 monoclonal antibody (10 µg·mL−1),
and control mouse IgG (10 µg·mL−1) added during the 2 weeks of ALI differentiation on vimentin expression assessed
by immunohistochemistry. b) Quantification of vimentin staining (n=6; filled symbols represent chronic obstructive
pulmonary disease (COPD) patients). c) Morphological aspect of air-liquid interface (ALI)–human broncho-epithelial
cells (HBEC) with and without anti-TGF-β1 antibody. d) Fibronectin release by ALI–HBEC treated by TGF-β1,
anti-TGF-β1 antibody or control mouse immunoglobulin G (mIgG) during the 2 weeks of ALI differentiation (n=6).
e) Fibronectin release assessed in ALI–HBEC incubated with increasing concentrations of anti-TGF-β1 antibody (n=2;
with each condition in triplicate). #: p=0.03 versus nontreated ALI–HBEC. Scale bars=50 µm.
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EMT could represent a continuous process along COPD airways. This large series allowed us to correlate
findings to lung functional indices of airflow limitation. Interestingly, EMT features of the bronchial
epithelium observed in situ (such as vimentin-expressing epithelial cells) correlated with the severity of
airway obstruction. In addition, they also correlated with the RBM thickening, which is a salient feature of
asthma and also observed in COPD to a lesser extent [28, 29]. Moreover, by imaging small airway tissue we
observed a co-localisation of vimentin-expressing epithelial cells with thickness and fragmentation (clefts)
of the RBM and with subepithelial deposition of vimentin. It is therefore proposed that EMT could
contribute in COPD to peribronchial fibrosis and subsequently, to irreversible airway obstruction. The fact
that changes in ZO-1 and E-cadherin expression were not clearly observed at the mRNA level suggests that
they may relate to post-transcriptional regulation, as previously shown for these proteins [30, 31]. This
study helps to better understand the pathophysiology of airway fibrosis in COPD through EMT, which was
previously implicated in the alveolar epithelium for parenchymal fibrosis or for dysregulated migration
during cancer progression. In addition, it remains to study whether dysregulated EMT could represent a
common pathway underlying some associated disorders such as mixed emphysema/fibrosis phenotype or
the association between COPD and lung cancer.
The “memory” of EMT features in the bronchial epithelium reconstituted in vitro from airway tissue of
COPD patients is of particular interest. It has been reported that broncho-epithelial cells from COPD may
retain certain aberrant functions, such as for oxidative responses [32], interleukin-8/CXCL8 [33] or MMP-9
production [14]. We show here that broncho-epithelial cells from COPD display de-differentiation/
mesenchymal features which persist up to 2 weeks of ALI culture, and include increased fibronectin release.
Interestingly, these phenotypic signatures of the COPD epithelium correlated to some extent with
expression data (in situ) and with lung function tests (in vivo), further indicating that this in vitro ALI
system represents a valid tool to study epithelial changes in COPD. The possibility that increased numbers
of mesenchymal cells within the COPD bronchial epithelium result from the migration of progenitor cells
(and not from in situ de-differentiation of epithelial cells) [34], as shown in experimental lung fibrosis [11],
was excluded by the observation that these cells co-express epithelial and mesenchymal markers and that
EMT was recapitulated in vitro in ALI cultures where retinoic acid counteracts fibroblast growth [35],
indicating that the COPD bronchial epithelium is intrinsically abnormal. The contribution of other cells to
peribronchial fibrosis, as well as their interactions with epithelial cells, however needs further investigation.
We show that TGF-β1 is a regulatory factor that contributes to imprint the COPD epithelium with EMT
features. TGF-β has been linked to COPD in genetic studies [36, 37] and its expression is increased in the
COPD airway epithelium, both in large and small airways [38]. First, we confirmed that TGF-β promotes
EMT in ALI-HBEC, and that this occurs more specifically in basal cells, as previously reported [39].
Interestingly, the abnormal mesenchymal phenotype observed in ALI-HBEC from COPD patients did not
persist longer than two weeks of ALI culture. This reversibility may suggest that the in vivo
microenvironment is necessary to maintain the mesenchymal phenotype of COPD epithelial cells. It is
thus possible that the inflammatory and oxidative environment of COPD airways could condition the
aberrant epithelial imprinting by TGF-β. It is however known that TGF-β is induced in the airways of
mice exposed to cigarette smoke before inflammation is elicited [40]. In addition, broncho-epithelial cells
from COPD patients are primed to release more TGF-β [38]. Therefore, it could be speculated that
mesenchymal imprinting of the bronchial epithelium by TGF-β is an early event in cigarette
smoke-induced COPD, which it is maintained on the long term (even after smoking cessation) upon
mechanisms that remain to identify. Another hypothesis is that in vitro environment (e.g. retinoic acid),
while initially required to promote re-differentiation and related reactivation of abnormal features, finally
reverses the epithelial phenotype by affecting epigenetic modifications [41]. Finally, targeting TGF-β1 was
able to decrease mesenchymal features in vitro, in line with previous studies where anti-TGF-β treatment
was able to improve both airway pathology and emphysema [42].
In conclusion, this study indicates that EMT-related de-differentiation of the epithelium occurs in COPD
conducting airways and correlates with peribronchial fibrosis and with airflow limitation. These changes
are recapitulated in vitro, during ALI-driven re-differentiation of the epithelium, at least in part as a
consequence of TGF-β signalling. These data suggest that EMT is an important component of airway
disease in COPD and that its targeting could reveal an attractive therapeutic strategy to restore epithelial
barrier and integrity.
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